2.0-mm DES for Very Small Vessels: Are They Viable?

The reference vessel diameter is a fundamental factor for restenosis after coronary angioplasty even with drug-eluting stents. The smallest sized stents available are 2.25 mm in diameter, but even smaller vessels can be symptomatic.

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?

This was a prospective multicenter trial of the Resolute Onyx 2.0-mm zotarolimus-eluting stent. The primary endpoint was target lesion failure.


Read also: Effects of Cerebral Radiation on Interventional Cardiologists”.


Subjects with stable or unstable angina and target lesions ≤27 mm in length, and a reference vessel diameter ≥2.0 mm and <2.25 mm were eligible for enrollment. A subset of subjects underwent follow-up angiography at 13 months post-procedure.

 

A total of 101 subjects with 104 lesions were enrolled. Almost half of them had a history of diabetes. The rate of target lesion failure at 12 months was 5%, above the pre-specified efficacy goal of 19% (p < 0.001). The rates of target lesion revascularization and acute myocardial infarction were 2.0% and 3.0%, respectively.


Read also: Excellent Outcomes for the First Sirolimus Eluting Balloon Tested on Instent Restesosis”.


There were no episodes of device thrombosis and the rate of binary restenosis was 12%.

 

Conclusion

This is the first report of a drug-eluting stent with a dedicated size to treat lesions in vessels with a diameter <2.25 mm. The Resolute Onyx 2.0-mm zotarolimus-eluting stent was associated with a low rate of target lesion failure and late lumen loss, which enable treatment in extremely small vessels.

 

Editorial

Regular management options for the treatment of symptomatic vessels as small as these include balloon angioplasty or oversizing with a 2.25-mm DES.

 

The first option is associated with a rate of restenosis of at least 40%, and the second may risk perforation and distal dissection. If the stent is implanted below nominal pressure to prevent such risk, this may lead to malapposition and underexpansion, which might end up associated with thrombosis.

 

Drug-eluting balloons may also be an option, since they reduce the rates of reintervention when compared with conventional balloons. However, it should be noted that their performance has always been below that of DES.

 

Original title: First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions with Very Small Reference Vessel Diameter.

Reference: Matthew J. Price et al. J Am Coll Cardiol Intv 2017;10:1381–8.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...